Document is current
Any future updates will be listed below
-
Authors
Kaufhold, Isabell
Lewkowicz, Daniel
Seidel, Danila
Brinkkoetter, Paul Thomas
Kron, Florian
-
Funding
Funding for this research was provided by:
Samsung Bioepis
- License Information
-
More Information
Article History
Received: 16 March 2026
Accepted: 5 June 2026
First Online: 3 July 2026
Declarations
:
: Not applicable.
: Not applicable.
: I Kaufhold, D Lewkowicz, D Seidel and F Kron are employees of the VITIS Healthcare Group, which was sponsored by Samsung Bioepis in connection with the development of this manuscript. P Brinkkoetter received speaker honoraria and consultant fees from AstraZeneca, Alexion, Bayer, Boehringer-Ingelheim, Novartis, Roche, Sanofi-Genzyme, Travere, Vifor CSL and participated in advisory boards for Alexion, Samsung Bioepis, Sanofi-Genzyme, Novartis, TaregED Biopharmaceuticals, Travere, Takeda, Vifor CSL and Bayer. He declares research funding from the German Research Foundation BR-2955/8 and Sanofi-Genzyme.
